Cathepsin B like cysteine proteases representing a major component of the lysosomal proteolytic repertoire plays an important role in intracellular protein degradation. Comparative models of cathepsin B (CatB) protein of six different Leishmania strains were developed using MODELLER. The modeled three-dimensional (3-D) structure has the correct stereochemistry as gauged from the Ramachandran plot and good 3-D structure compatibility as assessed by PROCHECK and the DOPE score (DS2.1, Accelrys). The modeled proteins were energy minimized and validated using standard dynamic cascade protocol (DS 2.1). Seven different disulfide bonding sites are predicted in CatB protein of Leishmania. Two domains were identified and different motifs are present in catB protein of Leishmania like aspargine glycosylation site, protein kinase phosphorylation site, Protein kinase C activation site, N-myristoylation site. Considering that cathepsin B is essential for survival of Leishmania, including for virulence to the mammalian host, it may be viewed as an attractive drug target.
INTRODUCTION
Leishmaniasis, a vector-borne disease that is caused by obligate intra-macrophage protozoa (Leishmania) is endemic in large areas of the tropics, subtropics and the Mediterranean basin. This disease is characterized by both diversity and complexity [1] [2] [3] . Form World Health Organization (WHO) estimated the number of persons at risk to be around 350 million and the number of new cases to be 2,357,000 per year. It is caused by more than twenty leishmanial species and is transmitted to human's by-30 different species of phebotomine sand-flies [4] [5] [6] .
In muco-cutaneous leishmaniasis, patients suffer from progressively destructive ulcerations of the mucosa, extending from the nose and mouth to the pharynx and larynx. These lesions are not self-healing and are usually seen months or years after a first episode of cutaneous leishmaniasis, when the macrophages of the nasooropharygeal mucosa become colonized, Leishmania braziliensis is responsible for most cases of muco-cutaneous leishmaniasis [7] [8] [9] .
Current drug treatment for Leishmania is either lacking or unsatisfactory and new drugs for clinical use are too expensive to develop through classical empirical screening methods. Research is now being directed toward identifying key differences between the metanolism of host and parasite as target for drug development. Current treatments for leishmaniasis have several side effects. The demand for chemotherapeutic agents for the treatment of kala azar is desperate. Those needing treatment are mainly in impoverished rural and rural and urban communities with poor housing and limited access to medical attention. Approved chemotherapies that are available were developed in the first half of the last century (Suramine, Pentamidine, Arsenicals and Antimonial); some would fail today's more stringent standards for drug safety. Given the initial success of a largely empirical approach, progress in drug development in recent years has been diseases by parasite Leishmania. In view of the economies of the Third World countries suffering most from these diseases, such drugs will have to be cheap and simple to administer [10] [11] [12] .
MATERIALS AND METHODS
The software and tool, which are used for searching journal, protein analysis, for knowing sequence of protein and also comparing the sequence, modeling of protein comparing 3D structure of protein, active site finding and molecular docking and ligand design, ADMET predication are the following: - The drugs like Phenelzine, Parzyline, Thiouridine, Nitrendipine, ehlorthalidone and Phoxim which shown good dock score from Discovery Studio as well as from GOLD were further assessed by pre ADMET (online tool) which shown very good HIA (human intestinal absorption) value, and negative carcinogenicity. After that QSAR studies were performed by TSAR software from that so many descriptors were obtained that could be used in determining new QSAR relationships.
These compounds may be used further for synthesis, their wet lab activity against enolase, animal model study and clinical trials and then can be implicated for the treatment of leishmaniasis. Those models are considered to be used in designing new leads for hopefully more active compounds.
